Human T-bet(+) B cell development is associated with BTK activity and suppressed by evobrutinib

Recent clinical trials have shown promising results for the next-generation Bruton’s tyrosine kinase (BTK) inhibitor evobrutinib in the treatment of multiple sclerosis (MS). BTK has a central role in signaling pathways that govern the development of B cells. Whether and how BTK activity shapes B cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Rijvers, Liza, van Langelaar, Jamie, Bogers, Laurens, Melief, Marie-José, Koetzier, Steven C., Blok, Katelijn M., Wierenga-Wolf, Annet F., de Vries, Helga E., Rip, Jasper, Corneth, Odilia B.J., Hendriks, Rudi W., Grenningloh, Roland, Boschert, Ursula, Smolders, Joost, van Luijn, Marvin M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462504/
https://www.ncbi.nlm.nih.gov/pubmed/35852869
http://dx.doi.org/10.1172/jci.insight.160909

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462504/
https://www.ncbi.nlm.nih.gov/pubmed/35852869
http://dx.doi.org/10.1172/jci.insight.160909

Ejemplares similares